AZD1208

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

AZD1208 is a novel, orally bioavailable, highly selective PIM kinase inhibitor with single nanomolar potency against all three PIM kinases.

AZD1208 is orally available, small molecule inhibitor of PIM kinases with potential antineoplastic activity. Pan-PIM kinase inhibitor AZD1208 inhibits the activities of PIM1, PIM2 and PIM3 serine/threonine kinases, which may result in the interruption of the G1/S phase cell cycle transition, thereby causing cell cycle arrest and inducing apoptosis in cells that overexpress PIMs. The growth inhibition of several leukemia cell lines by this agent is correlated with the expression levels of PIM1, which is the substrate of STAT transcription factors. PIM kinases are downstream effectors of many cytokine and growth factor signaling pathways and are upregulated in various malignancies.

AZD1208 ; AZD-1208

Others

Other Targets

Pim1; Pim2; Pim3

Cancer

——

1204144-28-4

379.48

C21H21N3O2S

98%

DMSO : 28.5 mg/mL 75.10 mM;

c1(c(cccc1/C=C/1\SC(=O)NC1=O)c1ccccc1)N1CCC[C@H](C1)N

5-[[2-[(3R)-3-Aminopiperidin-1-yl]biphenyl-3-yl]methylidene]-1,3-thiazolidine-2,4-dione

(-20℃)

With Ice Pack

≥ 2 years